The Microbiome theme has 10 member stock(s) today, with an average return of +3.5%. The leading stock is 랩지노믹스 (+17.0%, trading value 2,220,505,885).
Gut microbiome-based biotechnology, drawing attention for its potential to develop next-generation novel drugs for autoimmune diseases, obesity, and atopic dermatitis.
| Stock | Price | Return | Trading Value |
|---|---|---|---|
| 랩지노믹스 | 2,925 | +17.0% | 2,220,505,885 |
| 지놈앤컴퍼니 | 4,835 | +14.3% | 6,398,033,324 |
| 마크로젠 | 12,090 | +2.2% | 176,760,350 |
| 고바이오랩 | 2,665 | +2.1% | 48,296,965 |
| 비피도 | 2,635 | +0.4% | 3,444,650 |
| 소마젠 | 3,115 | +0.3% | 157,193,580 |
| CJ 바이오사이언스 | 3,710 | +0.1% | 25,243,910 |
| 종근당바이오 | 12,820 | -0.2% | 124,038,660 |
| HLB제넥스 | 1,787 | -0.7% | 331,168,053 |
| 유바이오로직스 | 8,240 | -1.0% | 634,368,535 |
This page's data is for reference only and is not investment advice. Actual market data may differ.